midostaurin
Arog Pharma Moving FLT3 Inhibitor Crenolanib Into Head-to-Head AML Trial Against First-Gen Rydapt
Premium
A Phase II trial of crenolanib plus chemo in FLT3-mutant AML demonstrated a robust complete response rate, particularly in younger patients.
Japanese Regulators Approve Invivoscribe Assay as CDx for Daiichi Sankyo AML Drug
The LeukoStrat CDx FLT3 Mutation Assay can now be used in Japan as the CDx for quizartinib for the treatment of FLT3-ITD positive relapsed or refractory AML.
The VA decided to bring this testing in house to streamline and standardize the process for doctors and gauge markers that are relevant to the veteran population.